Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 9/20 | 0.33 |
| ▸ | PLK1 | P53350 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267139 | 0.91 | ACACB (0.41) | ACACBACACAPARP1 | |
| SCHEMBL5914046 | 0.80 | AURKA (0.39) | AURKAKDRMAPK14ACACBACACA | |
| SCHEMBL5914262 | 0.79 | MAPK14 (0.37) | AURKAMAPK14 | |
| SCHEMBL5914172 | 0.76 | MAPK14 (0.35) | MAPK14 | |
| SCHEMBL5341690 | 0.75 | USP30 (0.48) | MAPK14 | |
| SCHEMBL5315409 | 0.72 | KDM4E (0.39) | MAPK14GSK3B | |
| SCHEMBL5341694 | 0.71 | MAPK14 (0.43) | MAPK14 | |
| SCHEMBL5264835 | 0.70 | ACACB (0.44) | AURKAACACBACACAPARP1 | |
| SCHEMBL5914334 | 0.65 | AURKA (0.38) | AURKAKDRMAPK14 | |
| SCHEMBL5914408 | 0.63 | CYP1A2 (0.40) | AURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | SCD 2449/4885AURKA 2082/4885KDR 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.